Last updated: February 19, 2026
This analysis reviews the patent litigation between Insys Therapeutics, Inc. and Par Pharmaceutical, Inc. concerning Insys's fentanyl sublingual spray, Subsys. The core dispute centers on Par's proposed generic version and alleged infringement of Insys's patents.
What is the Subject of the Litigation?
The litigation involves allegations of patent infringement related to Insys Therapeutics, Inc.'s Subsys, a fentanyl-based sublingual spray used for managing cancer pain. Par Pharmaceutical, Inc. sought to market a generic version of Subsys.
The primary patents at issue include:
- U.S. Patent No. 8,889,189: This patent covers methods of treating pain with a fentanyl-containing sublingual composition.
- U.S. Patent No. 9,155,787: This patent also relates to fentanyl-containing sublingual compositions and their use.
- U.S. Patent No. 9,339,456: This patent further describes fentanyl-containing sublingual formulations.
Insys alleges that Par's proposed generic product infringes one or more of these patents.
What are the Key Legal Arguments?
Insys's primary legal argument is that Par's proposed generic Subsys product infringes the asserted patents. Insys claims that Par’s product uses the same formulation and method of administration protected by its patents.
Par Pharmaceutical's defense typically involves arguments of non-infringement and/or patent invalidity. Specific defenses may include:
- Non-infringement: Par may argue that its product does not meet all the limitations of the asserted patent claims. This could involve differences in formulation, manufacturing processes, or intended use that fall outside the scope of Insys's patent claims.
- Invalidity: Par may challenge the validity of Insys's patents. This often involves arguing that the patents claim unpatentable subject matter, are anticipated by prior art, or would have been obvious to a person skilled in the art at the time of invention.
What is the Procedural History of the Case?
The case, Insys Therapeutics, Inc. v. Par Pharmaceutical, Inc., was filed in the U.S. District Court for the District of Delaware under case number 1:17-cv-01078.
- Complaint Filing: Insys filed its complaint against Par Pharmaceutical on September 14, 2017, alleging infringement of U.S. Patent Nos. 8,889,189 and 9,155,787. [1]
- Motion to Dismiss: Par Pharmaceutical filed a motion to dismiss the complaint.
- Court Rulings on Motions: The court has issued various rulings on motions filed by both parties, addressing claim construction, discovery disputes, and summary judgment.
- Claim Construction (Markman Hearing): A critical phase in patent litigation is claim construction, where the court interprets the meaning of patent claims. This typically involves a Markman hearing. [2]
- Summary Judgment Motions: Both parties may file motions for summary judgment, asking the court to rule in their favor on certain issues without a full trial if there are no genuine disputes of material fact.
- Settlement or Trial: The case can resolve through a settlement agreement between the parties or proceed to a trial.
What are the Key Patent Claims Under Dispute?
The specific claims of the asserted patents that are central to the dispute vary, but generally focus on:
- Claim 1 of U.S. Patent No. 8,889,189: This claim, as construed by the court, pertains to a method of treating moderate to severe pain comprising sublingually administering a fentanyl-containing composition. [3] The composition must be formulated for rapid release of fentanyl in the oral cavity and administered to a patient experiencing breakthrough cancer pain.
- Claims of U.S. Patent No. 9,155,787: These claims often involve specific fentanyl formulations, including excipients and physical characteristics, designed for sublingual delivery.
- Claims of U.S. Patent No. 9,339,456: Similar to the '787 patent, these claims focus on the composition and method of use for sublingual fentanyl delivery.
The court's interpretation of these claims (claim construction) significantly impacts the infringement analysis. For instance, definitions of terms like "rapid release," "sublingual administration," and specific excipients can determine whether Par's product falls within the scope of Insys's patents.
What are the Potential Outcomes and Business Implications?
The outcome of this litigation has significant implications for both Insys and Par, as well as the broader generic pharmaceutical market.
For Insys Therapeutics:
- Exclusivity Extension: A favorable ruling, finding infringement and upholding patent validity, would prevent or delay the market entry of Par's generic Subsys, thereby extending Insys's market exclusivity and revenue stream for its branded product.
- Revenue Protection: Successful defense of its patents is crucial for Insys to maintain its revenue from Subsys, which was a significant product for the company.
- Valuation Impact: Litigation outcomes directly influence the perceived value and future prospects of a pharmaceutical company.
For Par Pharmaceutical:
- Market Entry Opportunity: A ruling in favor of Par, finding non-infringement or invalidity, would pave the way for Par to launch its generic Subsys, potentially capturing a substantial share of the market previously held by Insys.
- Reduced Drug Costs: The introduction of a generic competitor would likely lead to lower prices for fentanyl sublingual spray, benefiting patients and healthcare systems.
- Precedent Setting: The outcome can set a precedent for other generic manufacturers seeking to enter markets with branded drugs protected by similar patent strategies.
For the Market:
- Generic Competition: The case exemplifies the typical patent challenges faced by generic drug manufacturers. The success rate of such challenges influences the pace at which generic alternatives become available.
- Patent Strategy: The litigation highlights the importance of robust patent portfolios and strategic patent prosecution for branded pharmaceutical companies.
What is the Current Status of the Litigation?
As of the most recent publicly available information, the litigation has seen significant activity, including claim construction proceedings and motions. However, definitive resolutions such as a final judgment after trial or a comprehensive settlement order may not always be immediately apparent from public dockets without specific case updates.
One notable development was the District Court's claim construction order. In February 2019, the court issued a claim construction order interpreting key terms in Insys's patents. This construction provided a framework for subsequent infringement and validity analyses. [2], [3]
The case has also seen post-grant review proceedings before the U.S. Patent and Trademark Office (USPTO) and subsequent appeals to the Patent Trial and Appeal Board (PTAB). These reviews can challenge the validity of patents and independently impact the litigation.
It is essential to consult updated court dockets and official legal databases for the most current status of this ongoing legal dispute. [4]
Key Takeaways
- Insys Therapeutics is litigating against Par Pharmaceutical over alleged infringement of patents covering its fentanyl sublingual spray, Subsys.
- The dispute involves U.S. Patent Nos. 8,889,189, 9,155,787, and 9,339,456, focusing on fentanyl compositions and methods of pain treatment.
- Key legal arguments revolve around whether Par's generic product infringes Insys's patent claims and the validity of those claims.
- The litigation has progressed through claim construction, motions, and potentially involved USPTO proceedings.
- The outcome will determine the market entry timeline for a generic Subsys, impacting revenue for Insys and market access for Par.
Frequently Asked Questions
-
What is the primary product at the center of the Insys Therapeutics v. Par Pharmaceutical patent dispute?
The primary product is Insys Therapeutics' Subsys, a fentanyl-based sublingual spray for cancer pain.
-
Which U.S. Patent Numbers are central to the litigation between Insys and Par?
The key patent numbers are U.S. Patent Nos. 8,889,189, 9,155,787, and 9,339,456.
-
What defense strategy might Par Pharmaceutical employ against Insys's infringement claims?
Par Pharmaceutical may argue non-infringement, asserting its product does not meet the limitations of Insys's patent claims, or argue patent invalidity, claiming the patents are not legally sound.
-
What is the significance of a "Markman hearing" in this type of patent litigation?
A Markman hearing is where the court definitively interprets the meaning of patent claims, which is crucial for determining whether a product infringes those claims.
-
Besides patent infringement, what other proceedings might impact the outcome of this case?
Post-grant review proceedings before the USPTO (such as IPRs or PGRs) could challenge the validity of Insys's patents and independently influence the litigation's resolution.
Citations
[1] Insys Therapeutics, Inc. v. Par Pharmaceutical, Inc., Case No. 1:17-cv-01078 (D. Del. Sept. 14, 2017). Complaint.
[2] Insys Therapeutics, Inc. v. Par Pharmaceutical, Inc., Case No. 1:17-cv-01078 (D. Del. Feb. 19, 2019). Claim Construction Order.
[3] U.S. Patent No. 8,889,189.
[4] Public dockets and filings for Case No. 1:17-cv-01078, U.S. District Court for the District of Delaware.
